Skip to main content
Erschienen in: Heart and Vessels 11/2017

06.06.2017 | Original Article

Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction

verfasst von: Tomohiro Fujisaka, Shu-ichi Fujita, Daichi Maeda, Kensaku Shibata, Hideaki Takahashi, Hideaki Morita, Yoshihiro Takeda, Takahide Ito, Koichi Sohmiya, Masaaki Hoshiga, Nobukazu Ishizaka

Erschienen in: Heart and Vessels | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Serum levels of the soluble urokinase-type plasminogen activator receptor (suPAR) reflect immune and inflammatory activation, and are shown to be associated with cardiovascular outcomes. We herein investigated the potential association between suPAR and left ventricular diastolic dysfunction among patients with preserved left ventricular ejection fraction (LVEF) and sinus rhythm. Among 291 patients who had sinus rhythm and an LVEF of ≥50% enrolled in the study, 26 (8.9%) were considered to have diastolic dysfunction. Patients with diastolic dysfunction had lower estimated glomerular filtration rate (eGFR), and higher systolic blood pressure (BPs), BNP, C-reactive protein, and suPAR than those without diastolic dysfunction. As compared with the first suPAR quartile, the fourth suPAR quartile was significantly associated with both diastolic dysfunction with an odds ratio of 8.95 [95% confidence interval (CI), 1.04–77.0, P < 0.05] after adjusting for sex, age, BPs log(eGFR), CRP, and diuretic use. On the other hand, receiver-operating characteristic curve (ROC) analysis showed that addition of log(suPAR) to the combination of age, sex, and log(eGFR), CRP, and diuretic use did not significantly improve the prediction of diastolic dysfunction. Among cardiac patients with preserved LVEF, serum suPAR was associated with diastolic dysfunction independent of confounding factors by logistic regression analysis. However, according to the ROC analysis, the utility of suPAR as a biomarker for diastolic dysfunction may be limited from a clinical point of view.
Literatur
1.
Zurück zum Zitat Del Rosso M, Margheri F, Serrati S, Chilla A, Laurenzana A, Fibbi G (2011) The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des 17:1924–1943CrossRefPubMed Del Rosso M, Margheri F, Serrati S, Chilla A, Laurenzana A, Fibbi G (2011) The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des 17:1924–1943CrossRefPubMed
2.
Zurück zum Zitat Su SC, Lin CW, Yang WE, Fan WL, Yang SF (2016) The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets 20:551–566CrossRefPubMed Su SC, Lin CW, Yang WE, Fan WL, Yang SF (2016) The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets 20:551–566CrossRefPubMed
3.
Zurück zum Zitat Sandquist M, Wong HR (2014) Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol 10:1349–1356CrossRefPubMedPubMedCentral Sandquist M, Wong HR (2014) Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol 10:1349–1356CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, Liu Y (2016) Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Sci Rep 6:39481CrossRefPubMedPubMedCentral Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, Liu Y (2016) Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Sci Rep 6:39481CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C (2016) Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. Am J Emerg Med 34:375–380CrossRefPubMed Zeng M, Chang M, Zheng H, Li B, Chen Y, He W, Huang C (2016) Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis. Am J Emerg Med 34:375–380CrossRefPubMed
6.
Zurück zum Zitat Lomholt AF, Christensen IJ, Hoyer-Hansen G, Nielsen HJ (2010) Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 49:805–811CrossRefPubMed Lomholt AF, Christensen IJ, Hoyer-Hansen G, Nielsen HJ (2010) Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 49:805–811CrossRefPubMed
7.
Zurück zum Zitat Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F (2012) Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 32:500–509PubMed Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F (2012) Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 32:500–509PubMed
8.
Zurück zum Zitat Persson M, Engstrom G, Bjorkbacka H, Hedblad B (2012) Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the malmo diet and cancer study. Atherosclerosis 220:502–505CrossRefPubMed Persson M, Engstrom G, Bjorkbacka H, Hedblad B (2012) Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the malmo diet and cancer study. Atherosclerosis 220:502–505CrossRefPubMed
9.
Zurück zum Zitat Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis S, Sperling L, Quyyumi AA (2014) Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 3:e001118CrossRefPubMedPubMedCentral Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis S, Sperling L, Quyyumi AA (2014) Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 3:e001118CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sorensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A (2014) Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 237:60–66CrossRefPubMed Sorensen MH, Gerke O, Eugen-Olsen J, Munkholm H, Lambrechtsen J, Sand NP, Mickley H, Rasmussen LM, Olsen MH, Diederichsen A (2014) Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 237:60–66CrossRefPubMed
11.
Zurück zum Zitat Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J (2013) Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham risk score. Int J Cardiol 167:2904–2911CrossRefPubMed Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J (2013) Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham risk score. Int J Cardiol 167:2904–2911CrossRefPubMed
12.
Zurück zum Zitat Borne Y, Persson M, Melander O, Smith JG, Engstrom G (2014) Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 16:377–383CrossRefPubMed Borne Y, Persson M, Melander O, Smith JG, Engstrom G (2014) Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 16:377–383CrossRefPubMed
13.
Zurück zum Zitat Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, Ito T, Ishizaka N (2017) Serum soluble urokinase-type plasminogen activator receptor is associated with low left ventricular ejection fraction and elevated plasma brain-type natriuretic peptide level. PLoS ONE 12:e0170546CrossRefPubMedPubMedCentral Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, Ito T, Ishizaka N (2017) Serum soluble urokinase-type plasminogen activator receptor is associated with low left ventricular ejection fraction and elevated plasma brain-type natriuretic peptide level. PLoS ONE 12:e0170546CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, Matsuzawa Y, Akiyama E, Yamamoto E, Sakamoto K, Nagayoshi Y, Kaikita K, Sumida H, Kim-Mitsuyama S, Ogawa H (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57:861–869CrossRefPubMed Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, Matsuzawa Y, Akiyama E, Yamamoto E, Sakamoto K, Nagayoshi Y, Kaikita K, Sumida H, Kim-Mitsuyama S, Ogawa H (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57:861–869CrossRefPubMed
15.
Zurück zum Zitat Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H (2016) The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction. ESC Heart Fail 3:53–59CrossRefPubMed Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H (2016) The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction. ESC Heart Fail 3:53–59CrossRefPubMed
16.
Zurück zum Zitat Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT (2016) suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol 174:745–753CrossRefPubMed Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT (2016) suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol 174:745–753CrossRefPubMed
17.
Zurück zum Zitat Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefPubMed
18.
Zurück zum Zitat Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55:613–618CrossRefPubMed Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55:613–618CrossRefPubMed
19.
Zurück zum Zitat Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlof B, Aalto T, Roman MJ, Papademetriou V, Ibsen H, Rokkedal J, Devereux RB (2000) Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 35:6–12CrossRefPubMed Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlof B, Aalto T, Roman MJ, Papademetriou V, Ibsen H, Rokkedal J, Devereux RB (2000) Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 35:6–12CrossRefPubMed
20.
Zurück zum Zitat Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N (2016) Association between FGF23, alpha-Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. PLoS ONE 11:e0156860CrossRefPubMedPubMedCentral Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N (2016) Association between FGF23, alpha-Klotho, and cardiac abnormalities among patients with various chronic kidney disease stages. PLoS ONE 11:e0156860CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMed Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMed
22.
Zurück zum Zitat Devereux RB, James GD, Pickering TG (1993) What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens 6:211S–215SPubMed Devereux RB, James GD, Pickering TG (1993) What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens 6:211S–215SPubMed
23.
Zurück zum Zitat Mitter SS, Shah SJ, Thomas JD (2017) A test in context: E/A and E/e′ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol 69:1451–1464CrossRefPubMed Mitter SS, Shah SJ, Thomas JD (2017) A test in context: E/A and E/e′ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol 69:1451–1464CrossRefPubMed
24.
Zurück zum Zitat Sato W, Kosaka T, Koyama T, Ishida M, Iino K, Watanabe H, Ito H (2013) Impaired renal function is a major determinant of left ventricular diastolic dysfunction: assessment by stress myocardial perfusion imaging. Ann Nucl Med 27:729–736CrossRefPubMedPubMedCentral Sato W, Kosaka T, Koyama T, Ishida M, Iino K, Watanabe H, Ito H (2013) Impaired renal function is a major determinant of left ventricular diastolic dysfunction: assessment by stress myocardial perfusion imaging. Ann Nucl Med 27:729–736CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ (2016) Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 18:103–112CrossRefPubMed Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ (2016) Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 18:103–112CrossRefPubMed
26.
Zurück zum Zitat Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18:588–598CrossRefPubMed Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18:588–598CrossRefPubMed
27.
Zurück zum Zitat Gromadzinski L, Januszko-Giergielewicz B, Pruszczyk P (2014) Hypocalcemia is related to left ventricular diastolic dysfunction in patients with chronic kidney disease. J Cardiol 63:198–204CrossRefPubMed Gromadzinski L, Januszko-Giergielewicz B, Pruszczyk P (2014) Hypocalcemia is related to left ventricular diastolic dysfunction in patients with chronic kidney disease. J Cardiol 63:198–204CrossRefPubMed
28.
Zurück zum Zitat Nogi S, Fujita S, Okamoto Y, Kizawa S, Morita H, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N (2015) Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. Am J Physiol Heart Circ Physiol 309:H986–H994PubMed Nogi S, Fujita S, Okamoto Y, Kizawa S, Morita H, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N (2015) Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. Am J Physiol Heart Circ Physiol 309:H986–H994PubMed
29.
Zurück zum Zitat Okamoto Y, Fujita S, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N (2016) Association between circulating FGF23, alpha-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels 31:66–73CrossRefPubMed Okamoto Y, Fujita S, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N (2016) Association between circulating FGF23, alpha-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. Heart Vessels 31:66–73CrossRefPubMed
30.
Zurück zum Zitat Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J (2015) Soluble urokinase receptor and chronic kidney disease. N Engl J Med 373:1916–1925CrossRefPubMedPubMedCentral Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J (2015) Soluble urokinase receptor and chronic kidney disease. N Engl J Med 373:1916–1925CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47:962–968CrossRefPubMed Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47:962–968CrossRefPubMed
32.
Zurück zum Zitat Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119:159–176CrossRefPubMed Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119:159–176CrossRefPubMed
33.
Zurück zum Zitat Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113:321–327CrossRefPubMed Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113:321–327CrossRefPubMed
34.
Zurück zum Zitat Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M, Baugh J (2015) Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail 21:167–177CrossRefPubMed Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M, Baugh J (2015) Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail 21:167–177CrossRefPubMed
35.
Zurück zum Zitat Tang L, Han X (2013) The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67:179–182CrossRefPubMed Tang L, Han X (2013) The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 67:179–182CrossRefPubMed
36.
Zurück zum Zitat Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38:1418–1428CrossRefPubMedPubMedCentral Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38:1418–1428CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL (2015) suPAR: a new biomarker for cardiovascular disease? Can J Cardiol 31:1293–1302CrossRefPubMed Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL (2015) suPAR: a new biomarker for cardiovascular disease? Can J Cardiol 31:1293–1302CrossRefPubMed
38.
Zurück zum Zitat Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, Sperling L, Quyyumi AA, Samady H (2015) Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis 239:55–60CrossRefPubMed Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, Al-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, Sperling L, Quyyumi AA, Samady H (2015) Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis 239:55–60CrossRefPubMed
39.
Zurück zum Zitat Lyngbaek S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781–785CrossRefPubMed Lyngbaek S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781–785CrossRefPubMed
40.
Zurück zum Zitat Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263–271CrossRefPubMed Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263–271CrossRefPubMed
41.
Zurück zum Zitat Namba T, Masaki N, Matsuo Y, Sato A, Kimura T, Horii S, Yasuda R, Yada H, Kawamura A, Takase B, Adachi T (2016) Arterial stiffness is significantly associated with left ventricular diastolic dysfunction in patients with cardiovascular disease. Int Heart J 57:729–735CrossRefPubMed Namba T, Masaki N, Matsuo Y, Sato A, Kimura T, Horii S, Yasuda R, Yada H, Kawamura A, Takase B, Adachi T (2016) Arterial stiffness is significantly associated with left ventricular diastolic dysfunction in patients with cardiovascular disease. Int Heart J 57:729–735CrossRefPubMed
42.
Zurück zum Zitat Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N (2016) Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 4:312–324CrossRefPubMed Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N (2016) Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 4:312–324CrossRefPubMed
43.
Zurück zum Zitat du Plooy CS, Kruger R, Huisman HW, Rasmussen LM, Eugen-Olsen J, Schutte AE (2015) Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: the SAfrEIC study. Heart Lung Circ 24:298–305CrossRefPubMed du Plooy CS, Kruger R, Huisman HW, Rasmussen LM, Eugen-Olsen J, Schutte AE (2015) Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: the SAfrEIC study. Heart Lung Circ 24:298–305CrossRefPubMed
44.
Zurück zum Zitat Osawa K, Miyoshi T, Oe H, Sato S, Nakamura K, Kohno K, Morita H, Kanazawa S, Ito H (2016) Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people. Heart Vessels 31:499–507CrossRefPubMed Osawa K, Miyoshi T, Oe H, Sato S, Nakamura K, Kohno K, Morita H, Kanazawa S, Ito H (2016) Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people. Heart Vessels 31:499–507CrossRefPubMed
45.
Zurück zum Zitat Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, Yamashita T (2012) Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 76:607–611CrossRefPubMed Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, Yamashita T (2012) Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 76:607–611CrossRefPubMed
46.
Zurück zum Zitat Ndrepepa G, Cassese S, Braun S, Fusaro M, King L, Tada T, Schomig A, Kastrati A, Schmidt R (2013) A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 23:1195–1201CrossRefPubMed Ndrepepa G, Cassese S, Braun S, Fusaro M, King L, Tada T, Schomig A, Kastrati A, Schmidt R (2013) A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 23:1195–1201CrossRefPubMed
47.
Zurück zum Zitat Onoue Y, Izumiya Y, Hanatani S, Kimura Y, Araki S, Sakamoto K, Yamamoto E, Tsujita K, Tanaka T, Yamamuro M, Kojima S, Kaikita K, Hokimoto S, Ogawa H (2016) Fragmented QRS complex is a diagnostic tool in patients with left ventricular diastolic dysfunction. Heart Vessels 31:563–567CrossRefPubMed Onoue Y, Izumiya Y, Hanatani S, Kimura Y, Araki S, Sakamoto K, Yamamoto E, Tsujita K, Tanaka T, Yamamuro M, Kojima S, Kaikita K, Hokimoto S, Ogawa H (2016) Fragmented QRS complex is a diagnostic tool in patients with left ventricular diastolic dysfunction. Heart Vessels 31:563–567CrossRefPubMed
Metadaten
Titel
Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction
verfasst von
Tomohiro Fujisaka
Shu-ichi Fujita
Daichi Maeda
Kensaku Shibata
Hideaki Takahashi
Hideaki Morita
Yoshihiro Takeda
Takahide Ito
Koichi Sohmiya
Masaaki Hoshiga
Nobukazu Ishizaka
Publikationsdatum
06.06.2017
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 11/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-017-1002-7

Weitere Artikel der Ausgabe 11/2017

Heart and Vessels 11/2017 Zur Ausgabe

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.